Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension

Annals of Pharmacotherapy

Volumn 42, Issue 4, 2008, Pages 498-504

  Lesk, Mark R ^a   Koulis, Theodora ^b   Sampalis, Fotini ^b   Sampalis, John S ^b,c,f   Bastien, Natacha R ^d,e  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^e EXACCT Study Group

^f NONE   (Canada)

Author keywords

Dorzolamide timolol; Intraocular pressure; Latanoprost; Ocular hypertension; Open angle glaucoma

Indexed keywords

DORZOLAMIDE PLUS TIMOLOL; LATANOPROST;

ADD ON THERAPY; AGED; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EYE IRRITATION; FEMALE; GOUT; HEADACHE; HUMAN; INTERVENTION STUDY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; OPEN ANGLE GLAUCOMA; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TASTE DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CANADA; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; SULFONAMIDES; THIOPHENES; TIMOLOL; TREATMENT OUTCOME;

EID: 42049084385     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K565     Document Type: Article

References (22)

1. Uva MG, Longo A, Reibaldi M, Reibaldi A. The effect of timolol-dorzolamide and timolol-pilocarpine combinations on ocular blood flow in patients with glaucoma. Am J Ophthalmol 2006;141:1158-60.
2. Boyle JE, Ghosh K, Gieser DK, Adamsons IA. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology 1998;105:1945-51.
3. Clineschmidt CM, Williams RD, Snyder E, Adamsons IA. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology 1998;105:1952-9.
4. Harris A, Jonescu-Cuypers CP, Kagemann L, et al. Effect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucoma. Am J Ophthalmol 2001;132:490-5.
5. Konstas AG, Kozobolis VP, Lallos N, Christodoulakis E, Stewart JA, Stewart WC. Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%. Eye 2004;18:1264-9.
6. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48-56.
7. Newell FW. Ophthalmology: principles and concepts. 7th ed. St Louis, MO: Mosby-Year Book, 1992:368.
8. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79.
9. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-20.
10. Damji KF, Behki R, Wang L. Canadian perspectives in glaucoma management: setting target intraocular pressure range. Can J Ophthalmol 2003;38:189-97.
11. Harris A, Arend O, Kagemann L, Garrett M, Chung HS, Martin B. Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma. J Ocul Pharmacol Ther 1999;15:189-97.
12. Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res 2000;19:87-112.
13. Josefsson A, Sigurdsson SB, Bang K, Eysteinsson T. Dorzolamide induces vasodilatation in isolated pre-contracted bovine retinal arteries. Exp Eye Res 2004;78:215-21.
14. Costa VP, Harris A, Stefansson E, et al. The effects of antiglaucoma and systemic medications on ocular blood flow. Prog Retin Eye Res 2003; 22:769-805.
15. Neufeld AH, Bartels SP, Liu JH. Laboratory and clinical studies on the mechanism of action of timolol. Surv Ophthalmol 1983;28(suppl):286-92.
16. Neufeld AH. Tales of two drugs. J Glaucoma 2005;14:1-2.
17. Stewart WC. Perspectives in the medical treatment of glaucoma. Curr Opin Ophthalmol 1999;10:99-108.
18. Pfeiffer N. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 2002;240:893-9.
19. Reis R, Queiroz CF, Santos LC, Avila MP, Magacho L. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Clin Ther 2006;28:552-9.
20. Susanna R Jr, Nicolela MT, Oga E. Additive effect of latanoprost to the combination of timolol and dorzolamide. J Glaucoma 2000;9:183-6.
21. Tsukamoto H, Noma H, Mukai S, Ikeda H, Mishima HK. The efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamide. J Ocul Pharmacol Ther 2005;21:395-9.
22. Webers CAB, van der Valk R, Schouten JSAG, Zeegers MP, Prins MH, Hendrikse F. Intraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol: a meta-analysis of randomized clinical trials. Ophthalmology 2007;114:40-6.